Volume 14 Supplement 1
Publication charges for this supplement were funded by 3P Solution, Milan, Italy. PAA has acted in a consultant/advisory role for BMS, Roche-Genentech, MSD, Ventana, Novartis and Amgen and has received research funding from BMS, Roche-Genentech and Ventana. The other Supplement Editors declare that they have no competing interests.
Naples, Italy1-5 December 2015
Edited by Paolo A Ascierto, Francesco M Marincola and Nicolar Mozzillo.
MELANOMA BRIDGE 2015
2022 Citation Impact
7.4 - 2-year Impact Factor
6.9 - 5-year Impact Factor
1.458 - SNIP (Source Normalized Impact per Paper)
1.544 - SJR (SCImago Journal Rank)
2023 Speed
9 days submission to first editorial decision for all manuscripts (Median)
86 days submission to accept (Median)
2023 Usage
4,999,990 downloads
8,678 Altmetric mentions